SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

Kimberly A. Kraynyak, PhD[1*], Elliott Blackwood, MS[1*], Joseph Agnes, PhD[1*], Pablo Tebas, MD[3], Mary Giffear, BS[1], Dinah Amante, BS[1], Emma L. Reuschel, PhD[2], Mansi Purwar, PhD[2], Aaron Christensen-Quick, PhD[1], Neiman Liu, MS[1], Viviane Andrade, PhD[1], Malissa C. Diehl, PhD[1], Snehal Wani, MS[1], Martyna Lupicka, PhD[1], Albert Sylvester, BS[1], Matthew P. Morrow, PhD[1], Patrick Pezzoli, BS[1], Trevor McMullan, MS[1], Abhijeet J. Kulkarni, MS[2], Faraz I. Zaidi, MS[2], Drew Frase, MS[2], Kevin Liaw, PhD[2], Trevor R.F. Smith, PhD[1], Stephanie J. Ramos, PhD[1], John Ervin, MD[4], Mark Adams MD[5], Jessica Lee, MPH[1], Michael Dallas, PhD[1], Ami Shah Brown, PhD, MPH[1], Jacqueline E. Shea, PhD[1], J. Joseph Kim, PhD[1], David B. Weiner, PhD[2], Kate E. Broderick, PhD[1], Laurent M. Humeau, PhD[1], Jean D. Boyer, PhD[1], Mammen P. Mammen Jr., MD[1#]

*Authors contributing equally

Affiliations:

[1]Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA

[2]Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA

[3]Hospital of the University of Pennsylvania, Philadelphia, PA, USA

[4]Alliance for Multispecialty Research, Kansas City, MO, USA

[5]Alliance for Multispecialty Research, Lexington, KY, USA

Running Title: SARS-CoV-2 DNA Vaccine Can be Boosted

Abstract Word Count: 199

Text Word Count: 3477

Meeting presentations:

In part at ID Week (September 2021), Virtual

#Corresponding author:

Mammen P. Mammen, Jr., MD

Inovio Pharmaceuticals

660W Germantown Pike, Suite #110

Plymouth Meeting, PA, 19462, USA.

Phone: (858) 410-3328

mammen.mammen@inovio.com

Abstract

Background: Additional SARS-CoV-2 vaccines that are safe and effective as both primary series and booster remain urgently needed to combat the COVID-19 pandemic. Here we describe the safety and durability of the immune response from two doses of a DNA vaccine (INO-4800) targeting the full-length Spike antigen and a subsequent homologous booster dose.

Methods: INO-4800 was evaluated in 120 healthy participants across three dose groups (0.5 mg, 1.0 mg and 2.0 mg), each stratified by age. INO-4800 was injected intradermally followed by electroporation at 0 and 4 weeks followed by an optional booster dose 6-10.5 months following the second dose.

Results: INO-4800 was well-tolerated, with no treatment-related serious adverse events reported. Most adverse events were mild in severity and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+T cells with lytic potential were detected in the 2.0 mg dose group.

Conclusion: INO-4800 was well-tolerated as a 2-dose series and as a homologous booster dose in all adults, including the elderly. These results support further development of INO-4800 as a primary series and as a booster.

Keywords: SARS-CoV-2; Clinical trial; DNA Vaccine; COVID-19; Immunogenicity; Booster

Trial Registration: ClinicalTrials.gov NCT04336410

Introduction

Despite aggressive vaccination campaigns, most of the world's population remains unvaccinated and susceptible to COVID-19, the disease caused by SARS-CoV-2[1]. To date, over 3.8 million people have succumbed to COVID-19[2]. The urgent need remains for additional safe and effective vaccines against SARS-CoV-2 that are affordable, scalable and can be distributed to countries where the infrastructure may not be supportive of ultra-cold chain transport and storage.

The preliminary safety and immunogenicity of the COVID-19 DNA vaccine, INO-4800, in both Phase 1 and Phase 2 clinical studies were previously reported[3, 4]. INO-4800 targets the SARS-CoV-2 spike protein which exists as a trimer on the virus surface. Attachment to host cells is mediated by binding of the spike protein's receptor binding domain (RBD) onto angiotensin converting enzyme 2 (ACE2) receptors of host cells[5]. Once attached, the viral transport through the host cell membrane is facilitated by the S2 region of spike protein[5]. Eliciting humoral and cellular responses against the spike protein can prevent the virus from gaining access to host cells, and this strategy has led to several impactful vaccine developments.

INO-4800 consists of an optimized plasmid DNA that is injected into the skin with enhanced delivery into the cells by in vivo electroporation[6]. This approach potentially offers several advantages, including induction of humoral and cellular immunity, favorable tolerability and thermal stability profiles and its ease of manufacture[7, 8].

The previous preliminary analysis[3] demonstrated that two 1.0 mg or 2.0 mg doses of INO-4800 administered one month apart were well-tolerated in 38 healthy participants 18-50 years of age and induced the production of neutralizing antibodies and/or T-cells targeting SARS-CoV-2 spike protein using a two-dose regimen. Here we describe the durability of that response at 6 months following the second dose, as well as the safety and immunogenicity of the 2-dose regimen in older and elderly participants including following a subsequent homologous booster dose.

25

26 **Methods**

27 Trial Design and Participants

28 The Phase 1, open-label, multi-center trial (NCT04336410) evaluated the safety, tolerability, and
29 immunogenicity of INO-4800 injected intradermally (ID) followed by electroporation (EP). A total
30 of 120 healthy participants without a known history of COVID-19 were assigned to receive a
31 0.5 mg, 1.0 mg, or 2.0 mg dose of INO-4800 in a 2-dose regimen (Weeks 0 and 4) and a
32 subsequent optional booster dose no earlier than 8-weeks after dose 2. An equal number of
33 participants were enrolled in each dose group (n=40) and further stratified by age groups [18-50
34 years of age; n=20, 51-64 years of age; n=10, and ≥65 years of age; n=10].

35 The trial was approved by the institutional review board of each clinical site and all participants
36 provided written informed consent prior to enrollment. The trial was conducted under current Good
37 Clinical Practices (GCP).

38

39 DNA Vaccine INO-4800

40 The DNA vaccine INO-4800 was previously described[3, 9]. Briefly, the vaccine expresses the
41 full-length sequence of the SARS-CoV-2 spike glycoprotein derived from the original Wuhan strain
42 based on an optimized synthetic sequence that was created using a proprietary algorithm. The
43 final vaccine drug product, manufactured under Good Manufacturing Practices, was formulated
44 at 10 mg/mL in saline sodium citrate buffer.

45 INO-4800 is injected ID immediately followed by EP using the CELLECTRA® 2000 device that
46 generates a controlled electric field at the injection site to enhance the cellular uptake and
47 expression of the DNA plasmid as previously described[10, 11]. The device delivers a total of four

48 electrical pulses per EP, each of 52 msec in duration, at current of 0.2 Amp and voltage of 40-
49 200 per pulse.

50

51 Endpoints

52 Primary safety endpoints included incidence of adverse events (AEs) using the "Toxicity Grading
53 Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trial"
54 including frequency and severity of injection site reactions. Primary immunological endpoints
55 included the measurement of SARS-CoV-2 Spike glycoprotein antigen-specific binding antibodies
56 as well as the measurement of antigen-specific cellular immune responses by IFN-γ, ELISPOT
57 and flow cytometry assays. Endpoints reflected in this publication are inclusive of 6 months after
58 second dose (non-boosted participants) and, when applicable, 2 weeks after booster dose.

59

60 Trial Procedures

61 Vaccine was administered in 0.1 ml ID injections in the deltoid region followed by EP at the
62 injection site. At each dosing visit, either a single injection for 0.5 mg and 1.0 mg dose groups or
63 two injections for 2.0 mg dose group were given, one in each deltoid region.

64 The initial forty participants 18-50 years were enrolled sequentially into 1.0 mg and 2.0 mg dose
65 groups with a safety run-in period[3]. The trial design was expanded to include older participants
66 in all dosing groups (including a 0.5 mg dose level). Upon favorable safety assessment review by
67 an independent Data Safety Monitoring Board (DSMB) of Week 1 data for 0.5 mg dose group

68 participants aged 51-64 years and ≥ 65 years, enrollment of the corresponding age strata in the
69 1.0 mg and subsequently 2.0 mg dose groups was initiated.

70 Participants were assessed for safety (complete blood count, serum chemistry, and urinalysis),
71 including local and systemic AEs, at serial time points [screening, Week 0 (Dose 1), next day
72 phone call, and Weeks 1, 4 (Dose 2), 6, 8, 12, 28, 40 and 52. Blood immunology collections
73 occurred at all clinic visits except Week 1. Upon completion of the Week 12 visit, participants who
74 consented to and received the optional booster dose were transitioned to an extended schedule
75 of events to include the booster dose (Dose 3) and subsequent visits for safety at 2, 12, 24, 36,
76 and 48 weeks following the booster dose with blood immunology collections at all clinic visits
77 except 36 weeks.

78 The DSMB reviewed laboratory and AE data for the participants up to 24 weeks after the second
79 dose (non-boosted) and 2 weeks after booster dose.

80

81 Protocol Eligibility

82 Key inclusion criteria included: healthy adults aged at least 18 years; and Body Mass Index of 18-
83 30 kg/m^2 at screening. Key exclusion criteria included: individuals in a current occupation with
84 high risk of exposure to SARS-CoV-2; previous known exposure to SARS-CoV-2 or receipt of an
85 investigational product for the prevention or treatment of COVID-19; autoimmune or
86 immunosuppression as a result of underlying illness or treatment; hypersensitivity or severe
87 allergic reactions to vaccines or drugs; and medical conditions that increased risk for severe
88 COVID-19.

89

90 Immunogenicity Assessment Methods

91 Samples were collected at timepoints described above with screening and pre-dose 1 samples
92 considered baseline. Peripheral blood mononuclear cells (PBMCs) were collected as previously
93 described[3]. After isolation, PBMCs were stored in the vapor phase of a liquid nitrogen freezer
94 until analysis, while serum samples were stored at -80°C. Eight participants were excluded from
95 the immunogenicity analyses due to a seropositive response, as determined by a positive ELISA
96 titer to the SARS-CoV-2 nucleoprotein, indicating SARS-CoV-2 infection

97 *SARS-CoV-2 Pseudovirus Neutralization Assay*: Serum samples were measured using a
98 pseudovirus neutralization assay as described previously[4]. Data was reported as ID_{50}, which is
99 the reciprocal serum dilution resulting in 50% inhibition of infectivity by comparison to control wells
100 with no serum samples added. Please see supplementary methods for additional information.

101 *SARS-CoV-2 Spike Enzyme-Linked Immunosorbent Assay (ELISA)*: Binding antibodies to SARS-
102 CoV-2 spike protein were measured by ELISA as described previously[4]. SARS-CoV-2 spike
103 antibody concentrations were determined by interpolation from a dilution curve of SARS-CoV-2
104 convalescent plasma with an assigned concentration of 20,000 Units per mL. Further details are
105 described in the supplementary methods.

106 *SARS-CoV-2 Spike ELISpot Assay Description*: The SARS-CoV-2 spike antigen-specific IFN-γ
107 T-cell response was measured as described previously[3]. Values were reported as the mean
108 spot-forming units per million PBMCs across three triplicate wells after background subtraction
109 using DMSO-only negative control wells. Please see supplementary methods for additional
110 information.

111 *INO-4800 SARS-CoV-2 Spike Flow Cytometry Assays:* PBMCs were also assessed in
112 Intracellular Cytokine Staining (ICS) and Lytic Granule Loading (LGL) assays. The ICS assay was
113 performed as previously described[3] and included cytokines IFNγ, TNFα, and IL-2. The LGL

114 assay was also performed as reported previously [12] following stimulation with overlapping
115 peptides to the full-length spike protein to measure CD8+T cell activation (CD38, CD69, CD137,
116 Ki67) and capacity to produce lytic proteins (granzymes A and B, perforin and granulysin).

117 Statistical Analysis

118 No formal power analysis was applicable to this trial. Descriptive statistics were used to
119 summarize the safety endpoints based on the safety population: proportions of participants with
120 AEs, through 6 months following dose 2 (non-boosted participants) or 2 weeks following booster
121 dose. The safety population included all participants who received at least one dose of INO-4800
122 and were grouped by age and the dose of INO-4800. Post-hoc within subject analyses of post-
123 vaccination minus pre-vaccination paired differences in SARS-CoV-2 neutralization and ELISA
124 spike responses (on the natural log-scale, with a paired t-test), ELISpot responses (with Wilcoxon
125 signed-rank tests), and flow assay responses (with Wilcoxon signed-rank tests) were performed.

126 **Results**

127 Trial Population Demographics

128 Between 06 April 2020 and 07 July 2020, 154 participants were screened and 120 enrolled into
129 the trial (**Figure 1**). The median age was 50.5 years (range 18 to 86 years). Participants were
130 57.5% female (69/120) and 42.5% male (51/120) (**Table 1**). Most participants were white (94.2%,
131 113/120).

132

133 Vaccine Safety and Tolerability

134 A total of 117 of 120 (97.5%) participants received both doses. One participant in the 2.0 mg
135 group discontinued trial participation prior to receiving the second dose solely due to lack of
136 transportation to the clinical site. Two participants in the 0.5 mg group did not receive the second
137 dose due to exclusionary eligibility criteria (hypertension) having been determined following Dose
138 1; (**Figure 1**).

139 Ninety-nine of 120 (82.5%) participants consented to and received the booster dose,
140 approximately 6 to 10.5 months following the second dose. Reasons for not receiving booster
141 dose included receipt of another SARS-CoV-2 vaccine (available under Emergency Use
142 Authorization), new medical condition precluding participation (having had COVID-19, pregnancy
143 or hypertension), or loss to follow-up.

144 A total of 34 treatment-related local and systemic AEs were reported by 18 participants. Thirty-
145 one AEs were Grade 1 (mild) in severity and comprised mostly injection site reactions. Three
146 treatment-related Grade 2 (moderate) AEs were reported as lethargy, abdominal pain, and
147 injection site pruritus. There were no febrile reactions reported. No participants discontinued due
148 to AEs. No treatment-related SAEs were reported. There were no abnormal laboratory values that

149 were deemed treatment-related and clinically significant by the Investigators. There was no
150 increase in the number of participants who experienced related AEs in the 2.0 mg group (12.5%,
151 5/40), compared to that in the 1.0 mg group (15%, 6/40) or the 0.5 mg group (17.5%, 7/40). In
152 addition, there was no appreciable increase in the frequency of AEs with the second or booster
153 doses when compared to the first dose (**Figure 2**). A decrease in frequency of treatment-related
154 AEs in the older and elderly age cohorts was observed when compared to the younger age group
155 (**Supplementary Figure 3**).

156

157 *INO-4800 induces durable humoral immune responses capable of being boosted*: The generation
158 of antibodies against SARS-CoV-2 following vaccination with INO-4800 was measured from the
159 sera. The functional ability of antibodies was assessed using a pseudovirus neutralization assay.
160 All three dose groups induced neutralizing antibodies that peaked two weeks following the second
161 dose (GMTs- 14.9, 19.1, 54.1 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively) (**Figure**
162 **3A, left panel, Supplementary Table 1**). These increased responses were statistically significant
163 over baseline in the 2.0 mg dose group for each time point through study week 28, approximately
164 6 months after dose 2 (**Figure 3A, table**). Following administration of a booster dose, statistically
165 significant increases over pre-boost titers were observed in all dose groups (GMTs- 58.7, 76.1,
166 100 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively; all $P<0.001$) (**Figure 3A, right**
167 **panel, Supplementary Table 1**). The 2.0 mg dose group had a 12.8 (95%CI 6.3, 26.0) geometric
168 fold rise (GMFR) over pre-boost titers, the highest of any dose group. Neutralization titers by
169 participant age are shown in **Supplementary Figure 1A;** GMTs were numerically lower in the

170 older age groups but statistically significantly higher than baseline at week 6 in the 2.0 mg dose
171 group**.**

172 Antibodies to the spike trimer protein were measured in a binding ELISA. All three dose groups
173 induced binding antibodies that peaked four weeks following dose 2 (GMTs- 428.5, 595.9, 678.0
174 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively) (**Figure 3B, left panel,**
175 **Supplementary Table 2**). Increases over baseline were observed in all participants who received
176 the 2.0 mg dose and GMTs were statistically significantly higher than baseline 6 months following
177 dose 2 (GMTs- 250.1, 215.3, 407.2 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively;
178 all $P \leq 0.026$). Following administration of a booster dose, statistically significant increases over
179 pre-boost titers were observed in all dose groups (GMTs- 1963.8, 3685, 5953 in the 0.5 mg, 1.0
180 mg and 2.0 mg dose groups, respectively; all $P \leq 0.007$) (**Figure 3B, right panel, Supplementary**
181 **Table 2**). The 2.0 mg dose group had a 20.8 (95%CI 13.9, 31.2) GMFR over pre-boost titers
182 which was the highest of any dose group. ELISA binding titers by participant age are shown in
183 **Supplementary Figure 1B.**

184 *INO-4800 induces cellular immune responses capable of being boosted*

185 Interferon-gamma (IFNγ) Enzyme-linked immunospot (ELISpot) was performed on PBMCs.
186 Increases in spot forming units (SFU) per million PBMCs over baseline are shown in **Figure 4A,**
187 **left panel**. Magnitudes of IFNγ peaked at week 6 for the 0.5 mg and 2.0 mg dose groups (median
188 19.4 and 43.3, respectively) and at week 8 for the 1.0 mg dose group (median 17.8). Six months
189 following dose 2, magnitudes remained high in the 2.0 mg dose group (median 19.6). Of note,
190 magnitudes in the 1.0 mg and 2.0 mg dose groups were statistically significantly increased
191 following the booster dose (P=0.018 and P=0.008, respectively) (**Figure 4A, right panel**). The
192 2.0 mg dose group had a difference in medians of 10 following the booster, resulting in the highest

193 post-boost increase of any dose group. ELISpot responses by participant age are shown in
194 **Supplementary Figure 2A.**

195 *INO-4800 induces cytokine producing T cells and activated CD8+T cells with lytic potential*

196 Further exploration of the T cell response was performed on participants following 2 doses. The
197 contribution of SARS-CoV-2 specific $CD4^+$ and $CD8^+$ T cells was assessed by intracellular
198 cytokine staining (ICS), **Figure 4B-C**. The median frequency of CD4+T cells producing IFNγ
199 increased following vaccination in all three dose groups of INO-4800, and the frequency of CD4+
200 T cells producing TNFα was statistically significantly increased in the 2.0 mg dose group
201 ($P<0.001$) (**Figure 4B**). The frequency of CD8+T cells producing TNFα was statistically
202 significantly increased following vaccination in all three dose groups of INO-4800 (All $P\leq0.041$)
203 (**Figure 4C**). The 2.0 mg dose group had the highest difference in medians for CD8+T cells
204 producing any response, IFNγ and TNFα (0.066, 0.026, and 0.011 respectively). ICS responses
205 by participant age are shown in **Supplementary Figure 2B-C.**

206 SARS-CoV-2 specific CD8+T cells were also characterized on a subset of participants with
207 remaining sample following 3 doses by a lytic granule loading flow cytometry assay that included
208 T cell receptor activation induced markers, CD69 and CD137. The median frequency of
209 CD8+CD69+CD137+ cells increased following immunization with 2.0 mg of INO-4800, with a
210 difference in the medians of 0.072 **(Figure 5A, left panel)**. Further characterization of these
211 activated cells, including the co-expression of proteins utilized in cytolytic killing (granzyme A,
212 granzyme B, perforin or granulysin) revealed a statistically significant increase in both the 1.0 mg
213 ($P=0.008$) and 2.0 mg ($P=0.003$) dose groups **(Figure 5A middle and right panels).** The 2.0 mg
214 dose group had a difference in medians of 0.085 in the CD69+CD137+ population co-expressing
215 perforin and granzymes A and B and 0.054 in the population co-expressing granulysin. CD8+T
216 cells expressing the activation marker CD38 and proliferation marker Ki67 were also assessed

217 **(Figure 5B and C, respectively).** The frequency of SARS-CoV-2 specific CD38+CD8+T cells
218 statistically significantly increased following 2.0 mg of INO-4800 (P=0.016), with a difference in
219 medians of 1.45 (**Figure 5B, left panel**). CD38+CD8+T cells with lytic potential (**Figure 5B**
220 **middle and right panels**) statistically significantly increased following 2.0 mg of INO-4800
221 (P<0.001). Following immunization with 2.0 mg of INO-4800, the mean frequency of activated
222 CD8+T cells expressing granzymes A and B and perforin was 1.7% with a difference in medians
223 of 0.710 and those expressing granulysin was 1.8% with a difference in medians of 0.433 (**Figure**
224 **5B middle and right panels)**. Statistically significant increases in the frequency of these CTL
225 phenotypes were also observed in the 1.0 mg dose group (P≤0.012) (**Figure 5B middle and**
226 **right panels**). The 2.0 mg dose group had the highest frequencies of CD8+T cells expressing
227 Ki67 with a difference in medians of 0.367 and Ki67 with cytolytic proteins: 0.296
228 (GrzA+GrzB+Prf+) and 0.230 (Gnly+). All three Ki67+ populations were statistically significantly
229 increased in the 2.0 mg dose group (P≤0.001; **Figure 5C)**. The 2.0 mg dose group consistently
230 showed the highest median responses across all phenotypes assessed when compared to the
231 other two dose groups.

232

233 **Discussion**

234 This report provides results for the expansion of a Phase 1 trial on the safety, tolerability, and
235 immunogenicity of INO-4800, a SARS-CoV-2 vaccine encoding the spike protein [3], including the
236 durability of the immune response 6 months following dose 2 and immune responses 2 weeks
237 following an optional booster dose.

238 INO-4800 appeared to be well-tolerated at all three dose levels, with no treatment-related serious
239 adverse events reported. Most adverse events were mild in severity and did not increase in
240 frequency with age and subsequent dosing. These safety and tolerability results are generally

241 consistent with U.S. Phase 2 trial results evaluating the 1.0 mg and 2.0 mg doses of INO-4800 in
242 approximately 400 subjects[4] and those studies conducted outside the U.S. by Inovio
243 collaborators (International Vaccine Institute, Advaccine – manuscripts in preparation).

244 Induction of both humoral and cellular responses were observed across all three dose groups in
245 the current trial, inclusive of binding and neutralizing antibodies and cytokine producing T cells as
246 well as exhibiting lytic potential in response to SARS-CoV-2 spike antigen. Immunization with the
247 2.0 mg dose of INO-4800 resulted in the highest GMTs of neutralizing and binding antibodies as
248 well as the highest magnitudes of IFNγ production to SARS-CoV-2 of any dose in all age groups
249 tested, and the increase in antibody levels were statistically significant above baseline out to 6
250 months following dose 2. Importantly, increases in both humoral and cellular immune responses
251 were statistically significant following the booster dose.

252 The contribution of the CD8+T cell response to vaccine efficacy has become increasingly
253 recognized as they have been detected early after vaccination[13] and due to their role in
254 controlling infection[14, 15]. Specifically, it has been established that CD8+T cells expressing
255 cytokines such as IFNγ and TNFα as well as markers involved in activation status and proliferation
256 such as CD38 and Ki67 contribute to limiting disease severity during SARS-CoV-2 infection[14].
257 Additional studies have identified the expression of CD69 and CD137 on SARS-CoV-2 specific
258 CD8+T cells being associated with less severe disease[15]. This expanded Phase 1 trial
259 demonstrates that immunization with INO-4800 induces SARS-CoV-2 specific CD8+ T cells
260 exhibiting these specific characteristics, suggesting the induction of a vaccine induced cellular
261 response that has potential to protect against severe COVID-19. As variants of concern continue
262 to emerge, the generation of cross-reactive activated CD8+T cells with lytic potential are likely to
263 play an important role in preventing severe disease. We have previously demonstrated that
264 vaccination with INO-4800 induces T cells and neutralizing antibodies that are active against the
265 parental SARS-CoV-2 strain as well as the Variants of Concern[16]. We acknowledge limitations

266 to this trial that include the relatively small study population and the limited number of PBMCs
267 available for testing across more than one assay. This trial was not powered to formally compare
268 immune responses between dose groups or age stratifications.

269 The immune responses observed in the current trial and in our larger Phase 2 trial [4] support
270 advancing the 2.0 mg dose of INO-4800 to a Phase 3 efficacy evaluation. This dose has elicited
271 the highest binding and neutralizing antibody titers, the highest T cell cytokine production from
272 both CD4+ and CD8+ T cells and the highest expression of markers associated with attenuation
273 of severe COVID-19 on CD8+ T cells (which could be critically important for vaccine efficacy in
274 preventing hospitalization and death in the context of the circulating Delta variant).

275 Our demonstration in this trial that the immune responses, both antibody as well as T cell
276 responses, elicited by a 2-dose primary series of INO-4800 could be further boosted with a third
277 dose without safety or tolerability concerns positions INO-4800 as an important candidate for
278 continued development as a stand-alone SARS-CoV-2 vaccine, as well as for continued
279 examination in combination approaches. The potential ability to administer INO-4800 multiple
280 times, with high tolerability, along with its ease of scalability and thermostability, contribute to its
281 potential value in combatting the COVID-19 pandemic and addressing the persistence of SARS-
282 CoV-2 as an ongoing endemic threat to global health.

Declaration of Interests

KAK, EB, JA, MG, DA, ACQ, NL, VA, MD, SW, ML, AS, MPM, PP, TM, TRFS, SJR, JL, MD, ASB, JES, JJK, KEB, LMH, JDB, MPM, Jr. report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial; other from Inovio Pharmaceuticals including salary and stock options, outside the submitted work. PT, ELR, MP, AJK, FIZ, DF, KL, JE, MA, and DBW report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial. D.B.W. participates in industry collaborations and has received renumeration for individual services. In the interest of disclosure, D.B.W. reports the following paid associations with commercial partners: Pfizer (Advisory Board), Geneos (Advisory, SRA), Advaccine (Advisory) Astrazeneca (Advisory, Speaker), Inovio (BOD, SRA, Stock ownership), Sanofi (Advisory Board), BBI (Advisory Board, SRA). All other authors declare no potential conflicts of interest.

Funding

This work is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Inovio Pharmaceuticals, Inc.

Acknowledgments

The investigators and sponsor express their gratitude for the contribution of all the trial participants and the invaluable advice of the international Data Safety Monitoring Board. We also acknowledge the broader support from the various teams within Inovio: [Ning Jiang, MD, PhD; Greta Kcomt Del Rio, BS; Alysia Ryan, BS; Dennis Van De Goor, MS; Kelly Morales, BS; Jacob Walton, BS; Srujan Vadlamudi, BS; David Valenta, PhD; EJ Brandreth, MBA; Dan Jordan, BS; Robert J. Juba Jr, MS; Stephen Kemmerrer, BSME, MBA, PE; Timothy Herring, MPH; Susan Duff, BS]; the Wistar Institute: Dr. Ziyang Xu and Edgar Tello Ruiz; National Infections Service,

Public Health England: Naomi Coombes, PhD; Mike Elmore, PhD and the Alliance for Multispecialty Research, Kansas City, MO and Lexington, KY.

References

1. Katz IT, Weintraub R, Bekker L-G, Brandt AM. From Vaccine Nationalism to Vaccine Equity — Finding a Path Forward. New England Journal of Medicine **2021**; 384:1281-3.

2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases **2020**; 20:533-4.

3. Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine **2021**; 31:100689.

4. Mammen MP, Tebas P, Agnes J, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv : the preprint server for health sciences **2021**:2021.05.07.21256652.

5. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell **2020**; 181:281-92.e6.

6. Gary EN, Weiner DB. DNA vaccines: prime time is now. Current Opinion in Immunology **2020**; 65:21-7.

7. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the Cold Reality of mRNA Vaccine Stability. Journal of Pharmaceutical Sciences **2021**; 110:997-1001.

8. Liu MA. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel) **2019**; 7:37.

9. Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun **2020**; 11:2601.

10. Tebas P, Kraynyak KA, Patel A, et al. Intradermal SynCon(R) Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. J Infect Dis **2019**; 220:400-10.

11. Tebas P, Roberts CC, Muthumani K, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med **2017**.

12. Aggarwal C, Cohen RB, Morrow MP, et al. Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. Vaccines (Basel) **2020**; 8.

13. Kalimuddin S, Tham CYL, Qui M, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med (N Y) **2021**; 2:682-8 e4.

14. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nature reviews Immunology **2020**; 20:529-36.

15. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell **2020**; 183:996-1012 e19.

16. Andrade VM, Christensen-Quick A, Agnes J, et al. INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants. bioRxiv **2021**:2021.04.14.439719.

Table 1: Participant Demographics

Variable	Statistic	0.5 mg (N=40)	1mg (N=40)	2mg (N=40)	Total (N=120)
Sex					
Male	n (%)	18 (45.0)	17 (42.5)	16 (40.0)	51 (42.5)
Female	n (%)	22 (55.0)	23 (57.5)	24 (60.0)	69 (45.0)
Race					
White	n (%)	40 (100)	38 (95.0)	35 (87.5)	113 (94.2)
Black or African American	n (%)	0	1 (2.5)	1 (2.5)	2 (1.7)
Asian	n (%)	0	1 (2.5)	4 (10.0)	5 (4.2)
Ethnicity					
Hispanic or Latino	n (%)	3 (7.5)	0	0	3 (2.5)
Not Hispanic or Latino	n (%)	35 (87.5)	40 (100)	40 (100)	40 (100.0)
Not Reported	n (%)	2 (5.0)	0	0	0
Age (years)	n	40	40	40	120
	Mean (SD)	50.7 (15.30)	49.2 (16.75)	50.7 (17.90)	50.2 (16.56)
	Median	52.5	51.0	50.5	50.5
	Min, Max	23, 76	18, 73	19, 86	18, 86

Figure 1: Consort Flow Diagram





Figure 2- Related systemic and local adverse events. Post First Dose, N=120 (N=40 in each dose group), Post Second Dose, N=117 (N=38 in the 0.5 mg dose group, N=40 in the 1.0 mg dose group and N=39 in the 2.0 mg dose group, and Post Third Dose, N=99 (N=33 in the 0.5 mg dose group, N=31 in the 1.0mg dose group and N=35 in the 2.0 mg dose group).


A
0.5mg Dose Group
1.0mg Dose Group
2.0mg Dose Group
ID50
4096
1024
256
64
16
4
1
Week 0
Week 6
Week 8
Week 12
Week 28
P<0.001
P<0.001
P<0.001
Pre-boost
Post-boost
B
S1+S2 Antibody (U/mL)
100000
10000
1000
100
Week 0
Week 4
Week 6
Week 8
Week 12
Week 28
P=0.007
P<0.001
P=0.002

significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).


A
SFU/10^6 PBMC
Increase Over Baseline
Week 0
Week 6
Week 8
Week 12
Week 28
P=0.018
P=0.008
Pre-boost
Post-boost
0.5mg Dose Group
1.0mg Dose Group
2.0mg Dose Group
B
% CD4 T Cells
P=0.045
P=0.011
P<0.001
Baseline
Post-Dose
Any Response
IFNg
IL2
TNFa
C
% CD8 T Cells
P=0.041
P=0.014
P=0.003
P=0.026
P< 0.001

the minimum to maximum values. The mean is denoted with a “+” sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg).



Figure 5- INO-4800 induces spike specific activated CD8+T cells with lytic potential. A lytic granule loading flow cytometry assay was used to characterize the expression of the activation markers CD69 and CD137 (A), CD38 (B), and the proliferation marker Ki67 (C) from samples collected at baseline or post-dose 2. The expression of proteins found in lytic granules: granzymes A (GrzA) and B (GrzB), perforin (Prf) and granulysin (Gnly) were assessed together with activation/proliferation subset. The graphs include n=4 participants in the 0.5 mg dose group and n=10 participants in the 1.0 mg dose group and n=13 in the 2.0 mg dose group. Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean

is denoted with a “+” sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).